Speaker illustration

Professor Erland Erdmann

University of Cologne, Cologne (Germany)

Member of:

European Society of Cardiology

From 1993 until 2012 I served as head of the university heart center Cologne. My main scientific interests are pathophysiology and treatment options of heart failure as well as the role of diabetes in cardiovascular disease. I have served in the steering committees of several major international drug and device trials directed to improve cardiovascular diseases such as CIBIS I, II and III, CARE-HF, PROACTIVE, SERVE-HF (all of which have been published in NEJM or The Lancet). Until 2025 I was editor of the main German textbook of cardiology (Klinische Kardiologie) 2024 in the 9th edition. Together with Nikolaus Marx/Aachen University this German Textbook was published 2025 as Clinical Cardiology, 2nd edition by Springer-Nature. Furthermore I serve in the ethics committee of the medical faculty of the University of Cologne/Germany.

Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure<sup> </sup>

Date: 9 July 2012

Journal: European Heart Journal

Thumbnail

Safety and tolerability of beta-blockers: prejudices and reality

Date: 1 March 2009

Journal: European Heart Journal Supplements

Thumbnail

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

Date: 1 January 2008

Journal: European Heart Journal

Thumbnail

ESC 365 is supported by